Freedom Capital Initiates Coverage of Tempus AI, Inc. (TEM)

Tempus AI, Inc. (NASDAQ:TEM) is one of the 10 Best Under-the-Radar Stocks to Invest In.

On July 1, Freedom Capital initiated coverage of Tempus AI, Inc. (NASDAQ:TEM) with a Hold rating. The firm gave a $59 price target on the shares. In an investor note, the firm noted that healthcare AI remains one of the fastest-growing technology segments. Most generative AI spending continues to flow to startups rather than established healthcare IT companies. Analyst Gene Mannheimer said Tempus has built one of the largest proprietary oncology data platforms, making it closer to the “AI as physician” thesis than any publicly traded healthcare technology company. However, he believes the valuation is appropriate at current levels.

On June 25, Tempus AI, Inc. (NASDAQ:TEM) announced a research collaboration with Angiosarcoma Awareness to advance fact-based research into angiosarcoma. The corporation said the effort will combine its analytical capabilities with approximately 600 de-identified angiosarcoma records containing paired DNA and RNA sequencing data. It will create one of the largest known disease-specific molecular datasets for the rare cancer.

Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology business. It combines artificial intelligence and machine learning with healthcare. It focuses on establishing platforms for cancer, neuropsychiatry, cardiology, infectious illness, and radiology.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.